STOCK TITAN

[8-K] QuidelOrtho Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Cushman & Wakefield plc (CWK) Form 4: Non-employee director Timothy H. Wennes was granted 11,873 restricted stock units (RSUs) on 01-Aug-2025 under the company’s 2018 Omnibus Non-Employee Director Share and Cash Incentive Plan. Each RSU converts 1-for-1 into ordinary shares.

The RSUs carry a $0 exercise price and will vest and settle on the first anniversary of the grant date, provided Wennes remains on the board. After this transaction he holds 11,873 derivative securities; no open-market purchase or sale occurred, so cash outlay and immediate dilution are zero.

The filing reflects routine director compensation intended to align board and shareholder interests. Because it does not represent a discretionary insider buy or material share issuance, the near-term market impact is considered neutral.

Cushman & Wakefield plc (CWK) Modulo 4: Il direttore non dipendente Timothy H. Wennes ha ricevuto 11.873 unità azionarie vincolate (RSU) il 01 agosto 2025 nell'ambito del Piano Incentivi Azionari e in Contanti per Direttori Non Dipendenti 2018 della società. Ogni RSU si converte 1 a 1 in azioni ordinarie.

Le RSU hanno un prezzo di esercizio di $0 e matureranno e saranno liquidate al primo anniversario della data di assegnazione, a condizione che Wennes rimanga nel consiglio. Dopo questa operazione detiene 11.873 strumenti derivati; non essendoci stato alcun acquisto o vendita sul mercato aperto, la spesa in contanti e la diluizione immediata sono pari a zero.

La comunicazione riflette una remunerazione ordinaria del direttore volta ad allineare gli interessi del consiglio e degli azionisti. Poiché non rappresenta un acquisto discrezionale da parte di un insider né un'emissione significativa di azioni, l'impatto sul mercato a breve termine è considerato neutrale.

Cushman & Wakefield plc (CWK) Formulario 4: El director no ejecutivo Timothy H. Wennes fue concedido 11,873 unidades de acciones restringidas (RSU) el 01 de agosto de 2025 bajo el Plan Omnibus 2018 de Acciones y Incentivos en Efectivo para Directores No Ejecutivos de la empresa. Cada RSU se convierte 1 a 1 en acciones ordinarias.

Las RSU tienen un precio de ejercicio de $0 y se consolidarán y liquidarán en el primer aniversario de la fecha de concesión, siempre que Wennes permanezca en la junta. Tras esta transacción, posee 11,873 valores derivados; no hubo compra ni venta en el mercado abierto, por lo que el desembolso en efectivo y la dilución inmediata son cero.

La presentación refleja una compensación rutinaria para directores destinada a alinear los intereses del consejo y los accionistas. Dado que no representa una compra discrecional por parte de un insider ni una emisión material de acciones, el impacto a corto plazo en el mercado se considera neutral.

Cushman & Wakefield plc (CWK) 양식 4: 비임원 이사인 Timothy H. Wennes는 2025년 8월 1일 회사의 2018년 비임원 이사 주식 및 현금 인센티브 통합 계획에 따라 11,873개의 제한 주식 단위(RSU)를 부여받았습니다. 각 RSU는 1대1로 보통주로 전환됩니다.

RSU는 행사가격이 $0이며, 부여일로부터 1주년이 되는 날에 Wennes가 이사회에 남아 있는 경우에만 취득 및 정산됩니다. 이번 거래 후 그는 11,873개의 파생 증권을 보유하며, 공개 시장에서의 매매가 없었으므로 현금 지출과 즉각적인 희석 효과는 없습니다.

이 보고는 이사회와 주주의 이익을 일치시키기 위한 일상적인 이사 보상을 반영합니다. 이는 내부자의 임의 매수나 중요한 주식 발행이 아니므로 단기 시장 영향은 중립적으로 간주됩니다.

Cushman & Wakefield plc (CWK) Formulaire 4 : Le directeur non salarié Timothy H. Wennes s’est vu attribuer 11 873 unités d’actions restreintes (RSU) le 1er août 2025 dans le cadre du Plan Omnibus de 2018 pour les directeurs non salariés en actions et incitations en espèces de la société. Chaque RSU se convertit en actions ordinaires à raison de 1 pour 1.

Les RSU ont un prix d’exercice de 0 $ et seront acquises et réglées à la date anniversaire de la remise, à condition que Wennes reste au conseil d’administration. Après cette transaction, il détient 11 873 titres dérivés ; aucune opération d’achat ou de vente sur le marché ouvert n’a eu lieu, donc la dépense en espèces et la dilution immédiate sont nulles.

Le dépôt reflète une rémunération de directeur de routine visant à aligner les intérêts du conseil et des actionnaires. Comme il ne s’agit pas d’un achat discrétionnaire d’initié ni d’une émission significative d’actions, l’impact à court terme sur le marché est considéré comme neutre.

Cushman & Wakefield plc (CWK) Formular 4: Der nicht geschäftsführende Direktor Timothy H. Wennes wurde am 01. August 2025 11.873 Restricted Stock Units (RSUs) im Rahmen des Omnibus-Plans 2018 für nicht geschäftsführende Direktoren der Gesellschaft gewährt. Jede RSU wandelt sich 1:1 in Stammaktien um.

Die RSUs haben einen Ausübungspreis von 0 $ und werden am ersten Jahrestag des Gewährungsdatums fällig und abgewickelt, vorausgesetzt, Wennes bleibt im Vorstand. Nach dieser Transaktion hält er 11.873 derivative Wertpapiere; da kein Kauf oder Verkauf am offenen Markt stattfand, sind Baraufwand und sofortige Verwässerung null.

Die Meldung spiegelt eine routinemäßige Vergütung des Direktors wider, die darauf abzielt, die Interessen von Vorstand und Aktionären in Einklang zu bringen. Da es sich nicht um einen diskretionären Insiderkauf oder eine wesentliche Aktienausgabe handelt, wird die kurzfristige Marktauswirkung als neutral eingestuft.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine RSU grant; aligns incentives, minimal investor impact.

The Form 4 shows Cushman & Wakefield awarding 11,873 RSUs to director Timothy H. Wennes. The award vests in 12 months, reinforcing board retention and share-price alignment. No cash changed hands and shares are not issued until vesting, so dilution is negligible against the company’s large float. Such scheduled grants are standard practice and do not carry the bullish signal of an open-market purchase. Accordingly, the disclosure is governance-neutral and unlikely to influence valuation or trading volumes.

Cushman & Wakefield plc (CWK) Modulo 4: Il direttore non dipendente Timothy H. Wennes ha ricevuto 11.873 unità azionarie vincolate (RSU) il 01 agosto 2025 nell'ambito del Piano Incentivi Azionari e in Contanti per Direttori Non Dipendenti 2018 della società. Ogni RSU si converte 1 a 1 in azioni ordinarie.

Le RSU hanno un prezzo di esercizio di $0 e matureranno e saranno liquidate al primo anniversario della data di assegnazione, a condizione che Wennes rimanga nel consiglio. Dopo questa operazione detiene 11.873 strumenti derivati; non essendoci stato alcun acquisto o vendita sul mercato aperto, la spesa in contanti e la diluizione immediata sono pari a zero.

La comunicazione riflette una remunerazione ordinaria del direttore volta ad allineare gli interessi del consiglio e degli azionisti. Poiché non rappresenta un acquisto discrezionale da parte di un insider né un'emissione significativa di azioni, l'impatto sul mercato a breve termine è considerato neutrale.

Cushman & Wakefield plc (CWK) Formulario 4: El director no ejecutivo Timothy H. Wennes fue concedido 11,873 unidades de acciones restringidas (RSU) el 01 de agosto de 2025 bajo el Plan Omnibus 2018 de Acciones y Incentivos en Efectivo para Directores No Ejecutivos de la empresa. Cada RSU se convierte 1 a 1 en acciones ordinarias.

Las RSU tienen un precio de ejercicio de $0 y se consolidarán y liquidarán en el primer aniversario de la fecha de concesión, siempre que Wennes permanezca en la junta. Tras esta transacción, posee 11,873 valores derivados; no hubo compra ni venta en el mercado abierto, por lo que el desembolso en efectivo y la dilución inmediata son cero.

La presentación refleja una compensación rutinaria para directores destinada a alinear los intereses del consejo y los accionistas. Dado que no representa una compra discrecional por parte de un insider ni una emisión material de acciones, el impacto a corto plazo en el mercado se considera neutral.

Cushman & Wakefield plc (CWK) 양식 4: 비임원 이사인 Timothy H. Wennes는 2025년 8월 1일 회사의 2018년 비임원 이사 주식 및 현금 인센티브 통합 계획에 따라 11,873개의 제한 주식 단위(RSU)를 부여받았습니다. 각 RSU는 1대1로 보통주로 전환됩니다.

RSU는 행사가격이 $0이며, 부여일로부터 1주년이 되는 날에 Wennes가 이사회에 남아 있는 경우에만 취득 및 정산됩니다. 이번 거래 후 그는 11,873개의 파생 증권을 보유하며, 공개 시장에서의 매매가 없었으므로 현금 지출과 즉각적인 희석 효과는 없습니다.

이 보고는 이사회와 주주의 이익을 일치시키기 위한 일상적인 이사 보상을 반영합니다. 이는 내부자의 임의 매수나 중요한 주식 발행이 아니므로 단기 시장 영향은 중립적으로 간주됩니다.

Cushman & Wakefield plc (CWK) Formulaire 4 : Le directeur non salarié Timothy H. Wennes s’est vu attribuer 11 873 unités d’actions restreintes (RSU) le 1er août 2025 dans le cadre du Plan Omnibus de 2018 pour les directeurs non salariés en actions et incitations en espèces de la société. Chaque RSU se convertit en actions ordinaires à raison de 1 pour 1.

Les RSU ont un prix d’exercice de 0 $ et seront acquises et réglées à la date anniversaire de la remise, à condition que Wennes reste au conseil d’administration. Après cette transaction, il détient 11 873 titres dérivés ; aucune opération d’achat ou de vente sur le marché ouvert n’a eu lieu, donc la dépense en espèces et la dilution immédiate sont nulles.

Le dépôt reflète une rémunération de directeur de routine visant à aligner les intérêts du conseil et des actionnaires. Comme il ne s’agit pas d’un achat discrétionnaire d’initié ni d’une émission significative d’actions, l’impact à court terme sur le marché est considéré comme neutre.

Cushman & Wakefield plc (CWK) Formular 4: Der nicht geschäftsführende Direktor Timothy H. Wennes wurde am 01. August 2025 11.873 Restricted Stock Units (RSUs) im Rahmen des Omnibus-Plans 2018 für nicht geschäftsführende Direktoren der Gesellschaft gewährt. Jede RSU wandelt sich 1:1 in Stammaktien um.

Die RSUs haben einen Ausübungspreis von 0 $ und werden am ersten Jahrestag des Gewährungsdatums fällig und abgewickelt, vorausgesetzt, Wennes bleibt im Vorstand. Nach dieser Transaktion hält er 11.873 derivative Wertpapiere; da kein Kauf oder Verkauf am offenen Markt stattfand, sind Baraufwand und sofortige Verwässerung null.

Die Meldung spiegelt eine routinemäßige Vergütung des Direktors wider, die darauf abzielt, die Interessen von Vorstand und Aktionären in Einklang zu bringen. Da es sich nicht um einen diskretionären Insiderkauf oder eine wesentliche Aktienausgabe handelt, wird die kurzfristige Marktauswirkung als neutral eingestuft.

0001906324false00019063242025-08-052025-08-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 5, 2025

QUIDELORTHO CORPORATION
(Exact name of Registrant as specified in its Charter)

Delaware
001-41409

87-4496285
 (State or other jurisdiction of incorporation)
 (Commission File Number)
 (IRS Employer Identification No.)

9975 Summers Ridge Road, San Diego, California 92121
(Address of principal executive offices, including zip code)
(858552-1100
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par ValueQDELThe Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 2.02    Results of Operations and Financial Condition.

On August 5, 2025, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its second quarter ended June 29, 2025 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on August 5, 2025 to discuss such results. A copy of the press release is furnished with this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1.

The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01    Financial Statements and Exhibits.
 (d)    Exhibits.
 The following exhibit is furnished with this Form 8-K:
  
Exhibit NumberDescription of Exhibit
99.1
Press release, dated August 5, 2025, reporting QuidelOrtho Corporation's financial results for its second quarter ended June 29, 2025.
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 5, 2025
   
QUIDELORTHO CORPORATION
  
By:/s/ Joseph M. Busky 
Name:Joseph M. Busky 
Its:Chief Financial Officer 


Quidel

NASDAQ:QDEL

QDEL Rankings

QDEL Latest News

QDEL Latest SEC Filings

QDEL Stock Data

1.60B
67.00M
0.92%
114.59%
9.24%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
SAN DIEGO